It's been suggested that the COMMERCIALIZATION AND LICENSE AGREEMENT and the SUPPLY AGREEMENT, both dated December 17, 2019, and both between Vyera Pharmaceuticals, LLC, and CytoDyn Inc. relate to the relationship of what constitutes control of CytoDyn's IP by Regnum through these agreements.
I'm not a contractual lawyer and these are pretty lengthy documents....any help from the crowd ?